Abstract

BackgroundMyalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a serious multifactorial disorder. The origin remains ambiguous, however reduced natural killer (NK) cell cytotoxicity is a consistent immunological feature of ME/CFS. Impaired transient receptor potential melastatin 3 (TRPM3), a phosphatidylinositol dependent channel, and impaired calcium mobilisation have been implicated in ME/CFS pathology. This investigation aimed to examine the localisation of TRPM3 at the NK cell plasma membrane and co-localisation with phosphatidylinositol 4,5-bisphosphate (PIP2). The effect of IL-2 priming and treatment using pregnenolone sulfate (PregS) and ononetin on TRPM3 co-localisation and NK cell cytotoxicity in ME/CFS patients and healthy controls (HC) was also investigated.MethodsNK cells were isolated from 15 ME/CFS patients and 15 age- and sex-matched HC. Immunofluorescent technique was used to determine co-localisation of TRPM3 with the NK cell membrane and with PIP2 of ME/CFS patients and HC. Flow cytometry was used to determine NK cell cytotoxicity. Following IL-2 stimulation and treatment with PregS and ononetin changes in co-localisation and NK cell cytotoxicity were measured.ResultsOvernight treatment of NK cells with PregS and ononetin resulted in reduced co-localisation of TRPM3 with PIP2 and actin in HC. Co-localisation of TRPM3 with PIP2 in NK cells was significantly reduced in ME/CFS patients compared with HC following priming with IL-2. A significant increase in co-localisation of TRPM3 with PIP2 was reported following overnight treatment with ononetin within ME/CFS patients and between groups. Baseline NK cell cytotoxicity was significantly reduced in ME/CFS patients; however, no changes were observed following overnight incubation with IL-2, PregS and ononetin between HC and ME/CFS patients. IL-2 stimulation significantly enhanced NK cell cytotoxicity in HC and ME/CFS patients.ConclusionSignificant changes in co-localisation suggest PIP2-dependent TRPM3 function may be impaired in ME/CFS patients. Stimulation of NK cells with IL-2 significantly enhanced cytotoxic function in ME/CFS patients demonstrating normal function compared with HC. A crosstalk exists between IL-2 and TRPM3 intracellular signalling pathways which are dependent on Ca2+ influx and PIP2. While IL-2R responds to IL-2 binding in vitro, Ca2+ dysregulation and impaired intracellular signalling pathways impede NK cell function in ME/CFS patients.

Highlights

  • Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/Chronic fatigue syndrome (CFS)) is a serious multifactorial disorder

  • Electrophysiology investigations reported a significant loss of transient receptor potential melastatin 3 (TRPM3) ion channel function in natural killer (NK) cells from Myalgic encephalomyelitis (ME)/CFS patients compared with healthy controls (HC) [5, 13, 14]

  • There was a significant increase in co-localisation values for TRPM3 with ­Phosphatidylinositol 4 (PIP2) in pregnenolone sulfate (PregS) (30 μM) + ononetin (3 μM) treated NK cells in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) patients compared with HC (PCC, p = 0.0408) (Fig. 6)

Read more

Summary

Introduction

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a serious multifactorial disorder. Impaired transient receptor potential melastatin 3 (TRPM3), a phosphatidylinositol dependent channel, and impaired calcium mobilisation have been implicated in ME/CFS pathology. While the aetiology remains elusive, ME/CFS may be described as a transient receptor potential (TRP) channelopathy with recent investigations having reported impaired TRPM3 (melastatin) ion channel function [5,6,7,8]. TRPM3 belongs to a superfamily of TRP ion channels that are widely expressed in a variety of cells and tissues including the sensory ganglia, central nervous system (CNS), pancreatic beta islets, cardiovascular cells, skeletal muscle cells, genitourinary and immune cells [7, 9] Due to their widespread expression in the body and their role in biological pathways, TRP ion channel dysfunction is implicated in diverse pathological states that may be categorised as channelopathies. These data highlight that mutations in the TRPM3 gene and TRPM3 ion channel dysfunction may provide a potential biomarker or therapeutic target for ME/CFS

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call